Please use this identifier to cite or link to this item:
Title: Molecular imaging with copper-64 in the drug discovery and development arena.
Authors: Smith, SV
Keywords: Drugs
Positron computed tomography
Copper 64
Clinical trials
Issue Date: 1-May-2007
Publisher: Informa Healthcare
Citation: Smith, S. V. (2007). Molecular imaging with copper-64 in the drug discovery and development arena. Expert Opinion on Drug Discovery, 2(5), 659-672. doi:10.1517/17460441.2.5.659
Abstract: The contribution of positron emission tomography (PET) to the drug discovery and development (D3) pipeline has been inhibited by the short half-lifes of PET radioisotopes, 11C and 18F, poor availability and the high cost of infrastructure. Copper-64 (64Cu) has a 12.7 h half-life, simple yet flexible radiochemistry and imaging characteristics that make it ideal for a wider application across the D3 arena. Recent scientific breakthroughs in the production of 64Cu show that it's, commercial production can be made more widely available. More importantly, for pharmaceutical research and development programmes wishing to incorporate the high sensitivity and spatial resolution of PET, but no desire to implement and maintain expensive radiochemistry infrastructure, 64Cu is an exciting option. © 2007, Informa Healthcare
Gov't Doc #: 2884
ISSN: 1746-0441
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.